Kern, W. and Braess, J. and Grote-Metke, A. and Kuse, H. and Fuchs, R. and Hossfeld, D. K. and Reichle, A. and Woermann, B. and Buechner, T. and Hiddemann, W. (1998) Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. LEUKEMIA, 12 (10). pp. 1522-1526. ISSN 0887-6924,
Full text not available from this repository.Abstract
In order to develop new strategies for the treatment of relapsed or refractory acute myeloid leukemia, the German AML Cooperative Group performed a prospective multicenter phase II study to evaluate the antileukemic efficacy of aclarubicin 60 mg/m(2)/day and etoposide 100 mg/m(2)/day each given for 5 days. Of 37 heavily pretreated evaluable patients (median age 42 years, range 18-81)15(40%) achieved a remission after one or two courses of treatment consisting of nine complete (24%) and six partial remissions (16%). Fourteen (38%) cases were non-responders and eight (22%) patients suffered from early deaths. Disease-free survival for patients in remission and overall survival were 3.2 months each. The median duration of critical neutropenia <500/mu l was 27 days. The most frequent non hematologic side-effects were stomatitis (WHO III/IV, 48%), infections (40%), nausea/vomiting (26%) and diarrhea (24%). Cardiac toxicity was mild. This study suggests a substantial antileukemic efficacy and an acceptable toxicity of aclarubicin in combination with etoposide in heavily pretreated patients with advanced acute myeloid leukemia, and warrants further evaluations in a more favorable stage of the disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACUTE MYELOGENOUS LEUKEMIA; DOSE CYTOSINE-ARABINOSIDE; SOUTHWEST-ONCOLOGY-GROUP; ACLACINOMYCIN-A; COOPERATIVE GROUP; EFFECTIVE REGIMEN; CROSS-RESISTANCE; ADRIAMYCIN; CHEMOTHERAPY; DAUNORUBICIN; acute myeloid leukemia; aclarubicin; etoposide; refractory disease |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 18 Apr 2023 13:25 |
| Last Modified: | 18 Apr 2023 13:25 |
| URI: | https://pred.uni-regensburg.de/id/eprint/49475 |
Actions (login required)
 |
View Item |
